Five major FDA Priority Review decisions are scheduled for September 2026, targeting rare genetic neurological conditions, FGFR2-mutated cholangiocarcinoma, and adolescent obstructive hypertrophic ...
FDA Fast Track designation for Aravax’s novel peptide immunotherapy PVX108 marks a significant milestone in expanding disease-modifying options for peanut allergy.
HealthDay News — There are considerable gaps in low-density lipoprotein cholesterol (LDL-C) control, especially among adults with established atherosclerotic cardiovascular disease (ASCVD), according ...
Higher rate of treatment success seen with omalizumab in intention-to-treat analysis, but not in per-protocol analysis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results